Future of HIV2 and HIV2 +  1 Infected Patients Treated with Antiretrovirals Followed at the Day Hospital HIV Care Unit from 2011 to 2015.

Autor: Diallo I; Department of Internal Medicine/Day Hospital (HIV Department), Yalgado Ouedraogo University Hospital, Ouagadougou, Burkina Faso.; Training and Research Unit Health Sciences (UFR-SDS), Joseph KI-Zerbo University, Ouagadougou, Burkina Faso., Ouédraogo S; Training and Research Unit Health Sciences (UFR-SDS), Joseph KI-Zerbo University, Ouagadougou, Burkina Faso.; Public Health Department, Yalgado Ouedraogo University Hospital, Ouagadougou, Burkina Faso., Sawadogo A; Department of Infectious Diseases, Regional Teaching Hospital of Ouahigouya, Ouahigouya, Burkina Faso., Ouédraogo GA; Department of Infectious Diseases, Yalgado Ouedraogo University Hospital, Ouagadougou, Burkina Faso., Diendéré EA; Department of Internal Medicine, Teaching Hospital of Bogodogo, Ouagadougou, Burkina Faso., Zoungrana J; Superior Institute of Health Sciences, Department of infectious diseases and tropical medicine, Nazi Boni University, Bobo Dioulasso, Burkina Faso., Sondo AK; Training and Research Unit Health Sciences (UFR-SDS), Joseph KI-Zerbo University, Ouagadougou, Burkina Faso.; Department of Infectious Diseases, Yalgado Ouedraogo University Hospital, Ouagadougou, Burkina Faso., Bognounou R; Department of Internal Medicine/Day Hospital (HIV Department), Yalgado Ouedraogo University Hospital, Ouagadougou, Burkina Faso., Savadogo M; Training and Research Unit Health Sciences (UFR-SDS), Joseph KI-Zerbo University, Ouagadougou, Burkina Faso.; Department of Infectious Diseases, Yalgado Ouedraogo University Hospital, Ouagadougou, Burkina Faso., Poda A; Superior Institute of Health Sciences, Department of infectious diseases and tropical medicine, Nazi Boni University, Bobo Dioulasso, Burkina Faso., Drabo YJ; Department of Internal Medicine/Day Hospital (HIV Department), Yalgado Ouedraogo University Hospital, Ouagadougou, Burkina Faso.; Training and Research Unit Health Sciences (UFR-SDS), Joseph KI-Zerbo University, Ouagadougou, Burkina Faso.
Jazyk: angličtina
Zdroj: Journal of the International Association of Providers of AIDS Care [J Int Assoc Provid AIDS Care] 2022 Jan-Dec; Vol. 21, pp. 23259582221143675.
DOI: 10.1177/23259582221143675
Abstrakt: Introduction: HIV2 is endemic in West Africa. In Burkina Faso, its prevalence was estimated at 2%. The aim of this work was to evaluate the follow-up of patients and also to contribute to the availability of data. Methods: We involved 18 years or older. Infection was screened according to the national algorithm. A cross- sectional study from first June 2017 to 31 December 2017 was performed. For each patient, sociodemographic, clinical, biological, therapeutic and evolution data were collected and analyzed. Results: The proportion of patients infected with HIV2 (n  =  48; 1.7%) and HIV2  +  1 (n  =  67; 2.4%) was 4.3%. The sex rat mean age was 50.3  ±  8.5 years. The combination of 2INTI  +  LPV/r was the most prescribed (n  =  73; 63.5%). The average gain of LTCD4 has evolved from + 236 cells/mm 3 in 2011 to + 364 cells/mm 3 in 2015. The retention rate at grade 5 was about 70%. Conclusion: The immunological and clinic response of the patients was satisfactory. More than half of the patients remained in the continuum of care after five years of follow-up.
Databáze: MEDLINE
Externí odkaz: